Business
Board change - appointment of new Chairman
Board change - appointment of new Chairman.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n\n \n\n\n\nFor immediate release\n\n\n 22 May 2023\n\n\n\n \nANGLE plc (\"the Company\")\n \nBOARD CHANGES - APPOINTMENT OF NEW CHAIRMAN\n \nANGLE plc (AIM: AGL; OTCQX: ANPCY), a world-leading liquid biopsy company announces that Garth Selvey has informed the Board of his intention to retire and leave ANGLE at the publication of the 2023 Interims in September. Garth will hand over the Chair with immediate effect to Dr. Jan Groen, currently an independent Non-executive Director on the Board.\n \nGarth joined ANGLE as a Non-executive Director in 2006 and became Chairman in 2007. Under his guidance, ANGLE has made significant progress in the development of its ground-breaking Parsortix® liquid biopsy system from its early adoption by leading cancer centres for oncology research through to its FDA clearance for use in metastatic breast cancer in May last year.\n \nDr. Jan Groen has over twenty years of experience in medical diagnostics covering both pharma and clinical sales, which provides critical market insight as ANGLE drives forward its commercial product roll-out and the expansion of its clinical laboratories and CTC services. Jan joined the ANGLE Board as a Non-executive Director in November 2018. Jan is currently the CEO and Chairman at Intravacc B.V. and was previously the CEO of MDxHealth, a Euronext listed genomic diagnostics company specialising in prostate cancer, and President and COO of Agendia, a company specialising in breast cancer. Jan's appointment as Chairman follows the new Non-executive Director appointments of Juliet Thompson and Dr. Joseph Eid earlier this year.\n \nANGLE Founder and Chief Executive, Andrew Newland, commented:\n\"I would like to thank Garth for his exceptional contribution to the ANGLE journey. His support and guidance has been gratefully received, especially during pivotal moments in the Company's development. He leaves ANGLE in a strong position to capitalise on its FDA product clearance and experiencing good momentum in both its product and services businesses. I am delighted that Jan has agreed to step into the Chairman role and look forward to his continued assistance in realising ANGLE's commercial potential.\"\n \n \nFor further information:\n \n\n\n\nANGLE plc\n\n\n+44 (0) 1483 343434\n\n\n\n\nAndrew Newland, Chief ...